Daewoong Readies Diabetes Contender Enavogliflozin, Aiming For '23 Launch
Benefits Over Competitors?
Executive Summary
With multiple South Korean INDs to begin Phase III trials with its SGLT-2 inhibitor enavogliflozin, Daewoong is aiming to speed domestic and global development of the potentially best-in-class drug for type 2 diabetes.